The Clinical Effect of Deferoxamine Mesylate on Edema after Intracerebral Hemorrhage

It has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients. The aim of this study was to investigate the efficacy of deferoxamine mesylate for edema resolution and hematoma absorption a...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 10; no. 4; p. e0122371
Main Authors: Yu, Yao, Zhao, Wei, Zhu, Chunpeng, Kong, Zhiping, Xu, Yan, Liu, Guangzhi, Gao, Xuguang
Format: Journal Article
Language:English
Published: United States Public Library of Science 13.04.2015
Public Library of Science (PLoS)
Subjects:
Absorption
Aged
Blood pressure
Brain Edema - complications
Brain Edema - drug therapy
Brain Edema - pathology
Brain research
Cerebral Hemorrhage - complications
Cerebral Hemorrhage - drug therapy
Cerebral Hemorrhage - pathology
Clinical trials
Coma
Computed tomography
Deferoxamine
Deferoxamine - administration & dosage
Discharge
Drug dosages
Edema
Female
Hematoma
Hemoglobin
Hemorrhage
Hospitals
Humans
Infusion
Internal medicine
Iron
Male
Medical imaging
Medical research
Middle Aged
Neurology
Patients
Research methodology
Stroke
Studies
Tomography, X-Ray Computed
Traumatic brain injury
Beijing China
China
ISSN:1932-6203, 1932-6203
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients. The aim of this study was to investigate the efficacy of deferoxamine mesylate for edema resolution and hematoma absorption after ICH. From February 2013 to May 2014, spontaneous ICH patients diagnosed by computed tomography (CT) within 18 hours of onset were evaluated. Patients were randomly divided into two groups: an experimental group and a control group. The treatment of the two groups was similar except that the experimental group received deferoxamine mesylate. Patients were evaluated by CT and neurology scale at the time of admission, and on the fourth, eighth, and fifteenth day (or at discharge) after admission. Patients were followed up for the first 30 days and clinical data of the two groups were compared. Forty-two patients completed 30 days of follow-up by May 2014; 21 cases in the experimental group and 21 cases in the control group. The control group's relative edema volume on the fifteenth day (or discharge) was 10.26 ± 17.54, which was higher than the experimental group (1.91 ± 1.94; P < 0.05). The control group's 1-8 day and 8-15 day relative hematoma absorption were greater than the experimental group (P < 0.05).The control group's relative edema volume on the fourth, eighth, and fifteenth day (or discharge) was higher than the experimental group (P < 0.05). Neurological scores between the two groups were not statistically different on the fifteenth day (or discharge) or on the thirtieth day. Deferoxamine mesylate may slow hematoma absorption and inhibit edema after ICH, although further investigation is required to form definitive conclusions. Chinese Clinical Trial Registry ChiCTR-TRC-14004979.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: XGG. Performed the experiments: XGG YY WZ CPZ ZPK YX GZL. Wrote the paper: XGG YY.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0122371